Matching articles for "Bydureon"
In Brief: Semaglutide (Wegovy) for Weight Loss in Children
The Medical Letter on Drugs and Therapeutics • February 20, 2023; (Issue 1670)
The injectable glucagon-like peptide-1 (GLP-1)
receptor agonist semaglutide (Wegovy), which was
approved by the FDA in 2021 for chronic weight
management in adults, has now been approved for
chronic weight...
The injectable glucagon-like peptide-1 (GLP-1)
receptor agonist semaglutide (Wegovy), which was
approved by the FDA in 2021 for chronic weight
management in adults, has now been approved for
chronic weight management in children ≥12 years old
with an initial BMI in the ≥95th percentile for age and
sex.Semaglutide is also available as Ozempic and
Rybelsus for treatment of type 2 diabetes in adults.
Drugs for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • November 14, 2022; (Issue 1663)
Diet, exercise, and weight loss can improve glycemic
control, but almost all patients with type 2 diabetes
require antihyperglycemic drug therapy. Treating to
a target A1C of...
Diet, exercise, and weight loss can improve glycemic
control, but almost all patients with type 2 diabetes
require antihyperglycemic drug therapy. Treating to
a target A1C of <7% while minimizing hypoglycemia
is recommended to prevent microvascular complications
of diabetes (retinopathy, nephropathy, and
neuropathy). An A1C target of <8% may be appropriate
for some older patients.
Drugs for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • November 4, 2019; (Issue 1584)
Diet, exercise, and weight loss can improve glycemic
control, but almost all patients with type 2 diabetes
eventually require drug therapy. Treating to a glycated
hemoglobin (A1C) concentration of...
Diet, exercise, and weight loss can improve glycemic
control, but almost all patients with type 2 diabetes
eventually require drug therapy. Treating to a glycated
hemoglobin (A1C) concentration of <7% can prevent
microvascular complications (retinopathy, nephropathy,
and neuropathy), but whether it prevents macrovascular
complications and death is unclear. An A1C target of
<8% may be appropriate for older patients and those
with underlying cardiovascular disease (CVD), a history
of severe hypoglycemia, diabetes-related complications,
a limited life expectancy, or a long duration of disease.
Oral Semaglutide (Rybelsus) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • October 21, 2019; (Issue 1583)
An oral formulation of the glucagon-like peptide-1
(GLP-1) receptor agonist semaglutide (Rybelsus –
Novo Nordisk) has been approved by the FDA
for once-daily treatment of type 2 diabetes in
adults....
An oral formulation of the glucagon-like peptide-1
(GLP-1) receptor agonist semaglutide (Rybelsus –
Novo Nordisk) has been approved by the FDA
for once-daily treatment of type 2 diabetes in
adults. Semaglutide, which has been available in
a subcutaneously-injected formulation (Ozempic)
since 2017, is the first GLP-1 receptor agonist to
become available for oral administration; the 4 other
GLP-1 receptor agonists currently available in the US
are administered by subcutaneous (SC) injection.
Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • February 25, 2019; (Issue 1566)
Since 2008, because of safety concerns, the FDA has
mandated that long-term cardiovascular outcomes trials
be conducted for all new drugs for type 2 diabetes.
Reductions in the incidence of macrovascular...
Since 2008, because of safety concerns, the FDA has
mandated that long-term cardiovascular outcomes trials
be conducted for all new drugs for type 2 diabetes.
Reductions in the incidence of macrovascular complications
in these trials with some sodium-glucose
co-transporter 2 (SGLT2) inhibitors and glucagon-like
peptide 1 (GLP-1) receptor agonists in patients at risk
for cardiovascular disease (see Table 1) have led to
new recommendations.
Semaglutide (Ozempic) - Another Injectable GLP-1 Receptor Agonist for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • January 29, 2018; (Issue 1539)
The FDA has approved semaglutide (Ozempic – Novo
Nordisk), a long-acting injectable GLP-1 (glucagon-like
peptide-1) receptor agonist, for once-weekly
treatment of adults with type 2 diabetes. It is the...
The FDA has approved semaglutide (Ozempic – Novo
Nordisk), a long-acting injectable GLP-1 (glucagon-like
peptide-1) receptor agonist, for once-weekly
treatment of adults with type 2 diabetes. It is the sixth
GLP-1 receptor agonist to be approved in the US.
Drugs for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • November 20, 2017; (Issue 1534)
The motor symptoms of Parkinson's disease (PD) are
caused primarily by degeneration of dopaminergic
neurons in the substantia nigra. The nonmotor
symptoms of the disease are thought to be caused...
The motor symptoms of Parkinson's disease (PD) are
caused primarily by degeneration of dopaminergic
neurons in the substantia nigra. The nonmotor
symptoms of the disease are thought to be caused by
degeneration of other neurotransmitter systems.
Cardiovascular Effects of Some Antidiabetic Drugs
The Medical Letter on Drugs and Therapeutics • August 14, 2017; (Issue 1527)
For many years, the goal of drug therapy for most
patients with type 2 diabetes has been to achieve
and maintain an A1C of...
For many years, the goal of drug therapy for most
patients with type 2 diabetes has been to achieve
and maintain an A1C of <7%. Achieving that goal
can prevent microvascular complications (diabetic
retinopathy, nephropathy, neuropathy), but whether it
prevents macrovascular complications (myocardial
infarction [MI], stroke) has been less clear. The FDA
now requires that cardiovascular safety studies be
performed for all new drugs for type 2 diabetes.1
Recent findings that some of the newer second-line
drugs for type 2 diabetes have cardiovascular benefits
have led to new interest in the cardiovascular efficacy
and safety of all antidiabetic drugs.
Lixisenatide for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • January 30, 2017; (Issue 1513)
The FDA has approved lixisenatide (Sanofi), a short-acting
injectable GLP-1 (glucagon-like peptide-1)
receptor agonist, for once-daily treatment of adults
with type 2 diabetes, both alone (Adlyxin) and in...
The FDA has approved lixisenatide (Sanofi), a short-acting
injectable GLP-1 (glucagon-like peptide-1)
receptor agonist, for once-daily treatment of adults
with type 2 diabetes, both alone (Adlyxin) and in a
fixed-ratio combination with insulin glargine (Soliqua
100/33). Lixisenatide has been available since 2013 in
many other countries as Lyxumia. It is the fifth GLP-1
receptor agonist to be approved in the US.
Drugs for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • January 16, 2017; (Issue 1512)
The goal of drug therapy for type 2 diabetes is
to achieve and maintain a near-normal glycated
hemoglobin (A1C) concentration without inducing
hypoglycemia; the target is generally an A1C of
≤7%. Treating...
The goal of drug therapy for type 2 diabetes is
to achieve and maintain a near-normal glycated
hemoglobin (A1C) concentration without inducing
hypoglycemia; the target is generally an A1C of
≤7%. Treating to this target has been shown to
prevent microvascular complications (retinopathy,
nephropathy, and neuropathy), but whether it prevents
macrovascular outcomes is unclear. An A1C target of
<8% may be appropriate for older patients and those
with underlying cardiovascular disease, a history of
severe hypoglycemia, diabetes-related complications
or comorbidities, or a long duration of disease.
Diet, Drugs, and Surgery for Weight Loss
The Medical Letter on Drugs and Therapeutics • February 16, 2015; (Issue 1462)
Adults with a body mass index (BMI) between
25 and 29.9 kg/m2 are considered overweight. Those
with a BMI ≥30 are considered obese. Losing even
a small amount of weight and increasing physical
activity...
Adults with a body mass index (BMI) between
25 and 29.9 kg/m2 are considered overweight. Those
with a BMI ≥30 are considered obese. Losing even
a small amount of weight and increasing physical
activity can prevent some of the complications
of obesity, particularly type 2 diabetes. Diet and
exercise are the preferred methods for losing weight,
but long-term failure rates are high. Several drugs
have been approved by the FDA for weight reduction,
but adherence is poor, adverse effects are common,
and patients usually regain the lost weight when
the drug is stopped. Bariatric surgery can produce
substantial weight loss and significantly reduce
obesity-related comorbidities; long-term data on its
safety are encouraging, but still limited. Guidelines
for the management of overweight or obese adults
have recently been published.
Two New GLP-1 Receptor Agonists for Diabetes
The Medical Letter on Drugs and Therapeutics • November 10, 2014; (Issue 1455)
Two new injectable GLP-1 (glucagon-like peptide-1)
receptor agonists, dulaglutide (Trulicity [trū li si tee] –
Lilly) and albiglutide (Tanzeum [tan' zee um] – GSK),
have been approved by the FDA for...
Two new injectable GLP-1 (glucagon-like peptide-1)
receptor agonists, dulaglutide (Trulicity [trū li si tee] –
Lilly) and albiglutide (Tanzeum [tan' zee um] – GSK),
have been approved by the FDA for once-weekly
treatment of type 2 diabetes. Other available GLP-1
receptor agonists include exenatide, which is approved
for injection twice daily (Byetta) or once weekly
(Bydureon), and liraglutide (Victoza), which is injected
once daily.
Drugs for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • March 1, 2014; (Issue 139)
The goal of drug therapy for type 2 diabetes is to achieve and
maintain a near-normal A1C concentration without
inducing hypoglycemia; the target is generally an A1C
of 10,000 patients with type 2...
The goal of drug therapy for type 2 diabetes is to achieve and
maintain a near-normal A1C concentration without
inducing hypoglycemia; the target is generally an A1C
of <7.0%. Treating to this target has been shown to
prevent the microvascular complications of retinopathy
and nephropathy, but whether it prevents macrovascular
outcomes remains unclear. Three large trials found
that intensive glucose control did not reduce the
incidence of macrovascular events. One of these trials
(ACCORD) in >10,000 patients with type 2 diabetes,
with or at high-risk for cardiovascular disease, found
that treating patients intensively with antihyperglycemic
drugs to an A1C target of 6.0% for a mean of 3.7 years
did not significantly reduce the incidence of major
cardiovascular events (the primary endpoint) and was
associated with increased all-cause mortality compared
to patients treated to an A1C target of 7.0-7.9%. An
A1C target of 7-8% may be prudent in older patients
and in those with underlying cardiovascular disease,
severe hypoglycemia, or multiple diabetes-related
complications or co-morbidities.
Canagliflozin (Invokana) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • May 13, 2013; (Issue 1416)
Canagliflozin (kan" a gli floe' zin; Invokana – Janssen),
a sodium-glucose co-transporter 2 (SGLT2) inhibitor,
has been approved by the FDA for oral treatment of
type 2...
Canagliflozin (kan" a gli floe' zin; Invokana – Janssen),
a sodium-glucose co-transporter 2 (SGLT2) inhibitor,
has been approved by the FDA for oral treatment of
type 2 diabetes.
What Comes After Metformin for Type 2 Diabetes?
The Medical Letter on Drugs and Therapeutics • July 23, 2012; (Issue 1395)
Most experts agree that lifestyle modifications and
metformin (Glucophage, and others) should be used
first to treat patients with type 2 diabetes. If metformin
alone fails to control hyperglycemia, there...
Most experts agree that lifestyle modifications and
metformin (Glucophage, and others) should be used
first to treat patients with type 2 diabetes. If metformin
alone fails to control hyperglycemia, there is
no general agreement on which drug should be
added next. A recent article in The Medical Letter
offered some support for a sulfonylurea. Three
recent trials published in The Lancet favored the
long-acting basal insulin glargine, the glucagon-like
peptide (GLP-1) analog exenatide, and the dipeptidyl
peptidase-4 (DPP-4) inhibitor linagliptin, respectively.
Some of the advantages and disadvantages of
these and other available agents are listed in Table 1
on the opposite page.
Extended-Release Exenatide (Bydureon) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • March 19, 2012; (Issue 1386)
The FDA has approved a once-weekly extendedrelease
formulation of exenatide (Bydureon – Amylin),
an injectable glucagon-like peptide-1 (GLP-1) receptor
agonist, for treatment of type 2...
The FDA has approved a once-weekly extendedrelease
formulation of exenatide (Bydureon – Amylin),
an injectable glucagon-like peptide-1 (GLP-1) receptor
agonist, for treatment of type 2 diabetes.
Liraglutide (Victoza) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • April 5, 2010; (Issue 1335)
Liraglutide (Victoza – Novo Nordisk), a glucagon-like peptide-1 (GLP-1) receptor agonist given by subcutaneous
injection, has been approved by the FDA for treatment of patients with type 2 diabetes. It can...
Liraglutide (Victoza – Novo Nordisk), a glucagon-like peptide-1 (GLP-1) receptor agonist given by subcutaneous
injection, has been approved by the FDA for treatment of patients with type 2 diabetes. It can be used alone or in addition to oral antidiabetic drugs such as metformin (Glucophage, and others) or glimepiride (Amaryl, and others). Liraglutide is not recommended for first-line therapy and is not approved for use with insulin.